Search
Treatment and survival of patients with chronic myeloid leukemia (CML) in Europe
Since the introduction of tyrosine kinase inhibitors into the treatment of CML survival times have greatly improved.
Read moreThe European Union must deliver funding for research of blood disorders
At the 20th Annual Congress of EHA, the results of two major projects are presented. The first is a study into the Cost of Blood Disorders in the EU Member States and Norway, Iceland, and Switzerland.
Read moreThe importance of education and collaboration for the treatment of patients
This article is written in the context of EHA’s membership of the European Alliance for Personalised Medicine (EAPM) where EHA takes a lead in the development of a strategy for education in personalized medicine. Read the full article here
Read moreDo generics of imatinib jeopardize patient safety for the sake of saving money? An experience in Turkish patients.
The high cost of tyrosine kinase inhibitors developed for chronic myeloid leukemia is a major concern for the health care payers, especially in countries with restricted resources.
European Hematologists will discuss breakthroughs in blood disorders in Milan, Italy - June 12-15, 2014
About the EHA Annual Congress
Hematology is a specialty that covers everything to do with blood: its origin in the bone marrow, diseases of blood and their treatments.
Major research funding calls are out now
First, the Innovative Medicines Initiative published its final call under the EU Seventh Framework Programme. Interestingly for hematologists, the call includes a project called ‘Blood-based biomarker assays for personalized tumour therapy: value of circulating biomarkers’.
Read moreSanquin Blood Supply will culture erythrocytes for transfusion purposes
ABO-Rh-D matched transfusions result in alloimmunisation in 3-5% of recipients. Once allo-immunized, it may become very difficult to find appropriate donor erythrocytes, especially when multiple antibodies or rare combinations of antibodies are present.
Read morePosition of EHA on Access to Medicines
There are many factors that compromise patient access to medicine. First and foremost, for a drug to be available, one has to be developed.
Press release: 18th Congress of the European Hematology Association in Stockholm, Sweden June 13-16-2013
The EHA-theme of the year, from June 2013 to June 2014, is dedicated to “Age and Aging in blood disorders”.
Read morePress release: Work of 2013 Nobel Prize in Physiology or Medicine winners to be presented at the 18th Congress of the European Hematology Association in Stockholm, June 13-16, 2013
With the Scientific Working Group for Stem Cells, the 18th Congress of EHA took the opportunity to acknowledge the work of the 2013 winner of the Nobel Prize for Medicine or Physiology, Drs John B.
Read more